TABLE OF CONTENTS
1 INTRODUCTION 57
1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF THE NORTH AMERICA DRUG MODELING SOFTWARE MARKET 57
1.4 CURRENCY AND PRICING 59
1.5 LIMITATIONS 59
1.6 MARKETS COVERED 59
2 MARKET SEGMENTATION 62
2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELING 69
2.7 COMPONENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 71
2.10 MARKET APPLICATION COVERAGE GRID 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
3.1 PORTER'S FIVE FORCES MODEL 78
3.2 VALUE CHAIN ANALYSIS 79
3.3 REGULATORY STANDARDS 80
3.4 TECHNOLOGICAL TRENDS 81
3.5 BENEFITS OF DRUG MODELING SOFTWARE 82
4 MARKET OVERVIEW 83
4.1 DRIVERS 85
4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 85
4.1.2 RISING DEMAND FOR NOVEL THERAPIES 87
4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 88
4.2 RESTRAINTS 89
4.2.1 LACK OF QUALITY DATA BASE 89
4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 89
4.3 OPPORTUNITIES 90
4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 90
4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 91
4.4 CHALLENGES 91
4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 91
4.4.2 CHALLENGES WITH MODEL INTERPRETATION 92
5 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 93
5.1 OVERVIEW 94
5.1.1 SOFTWARE 97
5.1.1.1 INTEGRATED 98
5.1.1.2 STANDALONE 98
5.1.1.3 LIGAND BASED 98
5.1.1.4 STRUCTURE BASED 98
5.2 SERVICES 98
5.2.1 PROFESSIONAL SERVICES 99
5.2.1.1 CONSULTING AND TRAINING 100
5.2.1.2 INTEGRATION AND IMPLEMENTATION 100
5.2.1.3 SUPPORT AND MAINTENANCE 100
5.2.2 MANAGED SERVICES 100
6 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 101
6.1 OVERVIEW 102
6.2 WINDOWS 105
6.3 LINUX 105
6.4 MAC OS 106
6.5 OTHERS 107
7 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 108
7.1 OVERVIEW 109
7.2 CLOUD BASED 112
7.3 HYBRID-BASED 112
7.4 ON-PREMISES 113
8 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 114
8.1 OVERVIEW 115
8.2 LARGE ENTERPRISE SIZE 118
8.3 SMALL & MEDIUM ENTERPRISE SIZE 118
9 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION 120
9.1 OVERVIEW 121
9.2 GRAPHICAL MOLECULAR MODELING 124
9.3 GENE SEQUENCE ANALYSIS 124
9.4 PROTEIN MODELING 125
9.5 MODELING CRYSTAL STRUCTURES 126
9.6 CHEMINFORMATICS 127
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 128
9.8 GAS & SOLUTION PHASE REACTION 128
9.9 MEDICAL IMAGING 129
9.10 OTHERS 130
10 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 131
10.1 OVERVIEW 132
10.2 SUBSCRIPTION BASED 135
10.2.1 ANNUALLY SUBSCRIPTION 136
10.2.2 MONTHLY SUBSCRIPTION 136
10.3 ONE-TIME LICENSE 136
10.3.1 GROUP LICENSE 137
10.3.2 DESKTOP LICENSE 137
10.3.3 OTHERS 137
11 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY END USER 138
11.1 OVERVIEW 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 142
11.2.1 LARGE ENTERPRISE SIZE 143
11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 143
11.3 CONTRACT RESEARCH ORGANIZATIONS 143
11.3.1 LARGE ENTERPRISE SIZE 144
11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 144
11.4 RESEARCH INSTITUTES 144
11.4.1 LARGE ENTERPRISE SIZE 145
11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 145
11.5 REGULATORY AUTHORITIES 145
11.5.1 LARGE ENTERPRISE SIZE 146
11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.6 OTHERS 147
11.6.1 LARGE ENTERPRISE SIZE 148
11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 148
12 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY REGION 149
12.1 NORTH AMERICA 150
12.1.1 U.S. 160
12.1.2 CANADA 165
12.1.3 MEXICO 170
13 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 175
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 175
14 SWOT ANALYSIS 176
15 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 177
15.1 DASSAULT SYSTEMES 177
15.1.1 COMPANY SNAPSHOT 177
15.1.2 REVENUE ANALYSIS 177
15.1.3 COMPANY SHARE ANALYSIS 178
15.1.4 PRODUCT PORTFOLIO 178
15.1.5 RECENT DEVELOPMENT 178
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 179
15.2.1 COMPANY SNAPSHOT 179
15.2.2 REVENUE ANALYSIS 179
15.2.3 COMPANY SHARE ANALYSIS 180
15.2.4 PRODUCT PORTFOLIO 180
15.2.5 RECENT DEVELOPMENTS 180
15.3 CERTARA, USA. 181
15.3.1 COMPANY SNAPSHOT 181
15.3.2 REVENUE ANALYSIS 181
15.3.3 COMPANY SHARE ANALYSIS 182
15.3.4 PRODUCT PORTFOLIO 182
15.3.5 RECENT DEVELOPMENTS 182
15.4 SCHRDINGER, INC. 183
15.4.1 COMPANY SNAPSHOT 183
15.4.2 REVENUE ANALYSIS 183
15.4.3 COMPANY SHARE ANALYSIS 184
15.4.4 PRODUCT PORTFOLIO 184
15.4.5 RECENT DEVELOPMENT 184
15.5 CRESSET. 185
15.5.1 COMPANY SNAPSHOT 185
15.5.2 COMPANY SHARE ANALYSIS 185
15.5.3 PRODUCT PORTFOLIO 186
15.5.4 RECENT DEVELOPMENTS 186
15.6 ACELLERA LTD 187
15.6.1 COMPANY SNAPSHOT 187
15.6.2 PRODUCT PORTFOLIO 187
15.6.3 RECENT DEVELOPMENTS 187
15.7 ARGUSLAB 188
15.7.1 COMPANY SNAPSHOT 188
15.7.2 PRODUCT PORTFOLIO 188
15.7.3 RECENT DEVELOPMENT 188
15.8 ATOMWISE INC. 189
15.8.1 COMPANY SNAPSHOT 189
15.8.2 PRODUCT PORTFOLIO 189
15.8.3 RECENT DEVELOPMENT 189
15.9 BC PLATFORMS 190
15.9.1 COMPANY SNAPSHOT 190
15.9.2 PRODUCT PORTFOLIO 190
15.9.3 RECENT DEVELOPMENTS 191
15.10 BIOSOLVEIT GMBH 192
15.10.1 COMPANY SNAPSHOT 192
15.10.2 PRODUCT PORTFOLIO 192
15.10.3 RECENT DEVELOPMENT 192
15.11 DOTMATICS 193
15.11.1 COMPANY SNAPSHOT 193
15.11.2 PRODUCT PORTFOLIO 193
15.11.3 RECENT DEVELOPMENTS 194
15.12 GENECODE 195
15.12.1 COMPANY SNAPSHOT 195
15.12.2 PRODUCT PORTFOLIO 195
15.12.3 RECENT DEVELOPMENT 195
15.13 INSILICOTRIALS TECHNOLOGIES. 196
15.13.1 COMPANY SNAPSHOT 196
15.13.2 PRODUCT PORTFOLIO 196
15.13.3 RECENT DEVELOPMENTS 197
15.14 NANOME INC. 198
15.14.1 COMPANY SNAPSHOT 198
15.14.2 PRODUCT PORTFOLIO 198
15.14.3 RECENT DEVELOPMENT 198
15.15 OPTIBRIUM, LTD. 199
15.15.1 COMPANY SNAPSHOT 199
15.15.2 PRODUCT PORTFOLIO 199
15.15.3 RECENT DEVELOPMENT 199
15.16 PHARMACELERA 200
15.16.1 COMPANY SNAPSHOT 200
15.16.2 PRODUCT PORTFOLIO 200
15.16.3 RECENT DEVELOPMENT 200
15.17 SIMULATIONS PLUS. 201
15.17.1 COMPANY SNAPSHOT 201
15.17.2 REVENUE ANALYSIS 202
15.17.3 COMPANY SHARE ANALYSIS 203
15.17.4 PRODUCT PORTFOLIO 203
15.17.5 RECENT DEVELOPMENT 204
15.18 THE SCRIPPS RESEARCH INSTITUTE 205
15.18.1 COMPANY SNAPSHOT 205
15.18.2 PRODUCT PORTFOLIO 205
15.18.3 RECENT DEVELOPMENT 205
15.19 VERISIM LIFE. 206
15.19.1 COMPANY SNAPSHOT 206
15.19.2 PRODUCT PORTFOLIO 206
15.19.3 RECENT DEVELOPMENTS 206
15.20 XTALPI INC. 207
15.20.1 COMPANY SNAPSHOT 207
15.20.2 PRODUCT PORTFOLIO 207
15.20.3 RECENT DEVELOPMENT 207
15.21 XYBION DIGITAL INC. 208
15.21.1 COMPANY SNAPSHOT 208
15.21.2 REVENUE ANALYSIS 208
15.21.3 PRODUCT PORTFOLIO 209
15.21.4 RECENT DEVELOPMENT 209
16 QUESTIONNAIRE 210
17 RELATED REPORTS 214

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.